STAB1/Stabilin-1/CLEVER-1 recombinant protein and antibody

STAB1, also widely known as CLEVER-1, encods protein called Stabilin-1. STAB1 is a large type I transmembrane scavenger receptor involved in angiogenesis, lymphocyte homing, cell adhesion, receptor scavenging, and ligand endocytosis. Public gene and literature resources indicate that STAB1 is primarily expressed in sinusoidal endothelial cells of the liver, spleen, and lymph node, and is also associated with non-classical monocytes, M2-polarized macrophages, and tumor-associated macrophages.

Mechanistically, STAB1/Stabilin-1 has emerged as a representative myeloid immunosuppressive target. In the tumor microenvironment, STAB1-high TAMs are associated with immune suppression, reduced T-cell infiltration, and impaired antitumor inflammation. Blocking STAB1 has been linked to macrophage repolarization toward a more pro-inflammatory phenotype, enhanced antigen presentation, and improved CD8+ T-cell activity. As a result, the main therapeutic focus for STAB1 currently lies in cancer immunotherapy, especially in advanced solid tumors and hematologic malignancies, while the broader research landscape also includes tumor microenvironment studies in breast cancer, colorectal cancer, melanoma, and glioblastoma.

From a drug-development perspective, the publicly visible clinical pipeline for STAB1 remains highly concentrated. The clinical-stage landscape is currently centered on one core therapeutic program, and the modality is a fully human IgG4 monoclonal antibody. There are two active Phase I/II studies spanning advanced solid tumors and high-risk MDS/relapsed or refractory AML. This makes monoclonal antibody therapy the dominant STAB1 drug modality at present, with future expansion likely to come from combination strategies built around myeloid immune reprogramming. For detailed progress, you can explore our blog titled “STAB1/Stabilin-1 in Macrophage Reprogramming and Tumor Immune Suppression”.

Currently, DIMA BIOTECH has developed four ECD recombinant proteins and two biosimilar reference antibodies. Recombinant proteins cover Human and Mouse species, with C-6×His Tag and C-Human Fc Tag formats. For a large multidomain scavenger receptor such as STAB1, high-quality extracellular domain proteins are particularly important for antibody screening, ligand binding studies, cell-surface expression evaluation, affinity analysis, and immunological assay development. Biosimilar reference antibodies include one unconjugated reference antibody and one biotinylated reference antibody, with application information including ELISA. DIMA BIOTECH is also advancing STAB1 flow cytometry antibody discovery through its proprietary single B cell monoclonal antibody platform, with selected candidates currently under internal screening and evaluation.